Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silmitasertib in Severe COVID-19
NCT04668209Phase 2Terminated
- Sponsor
- University of Arizona
- Start
- Jan 2021
- Primary completion
- Jun 2022
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of silmitasertib in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University of Arizona. Primary endpoint: Incidence of Treatment Emergent Adverse Events. Started Jan 2021; status: terminated.
02
Drugs
silmitasertib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04668209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04668209.